Mainz Biomed N.V.

BST:4TO Stock Report

Market Cap: €5.2m

Mainz Biomed Valuation

Is 4TO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 4TO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 4TO's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 4TO's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 4TO?

Key metric: As 4TO is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 4TO. This is calculated by dividing 4TO's market cap by their current revenue.
What is 4TO's PS Ratio?
PS Ratio5.8x
SalesUS$917.20k
Market CapUS$5.43m

Price to Sales Ratio vs Peers

How does 4TO's PS Ratio compare to its peers?

The above table shows the PS ratio for 4TO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average3x
CNW co.don
0.7xn/a€6.5m
MDG1 Medigene
3x16.1%€22.6m
ECX Epigenomics
7.7xn/a€1.2m
BPXA Bellicum Pharmaceuticals
0.5xn/a€772.4k
4TO Mainz Biomed
5.8x88.2%€5.4m

Price-To-Sales vs Peers: 4TO is expensive based on its Price-To-Sales Ratio (5.8x) compared to the peer average (4.2x).

Price to Sales Ratio vs Industry

How does 4TO's PS Ratio compare vs other companies in the DE Biotechs Industry?

6 CompaniesPrice / SalesEstimated GrowthMarket Cap
CNW co.don
0.7xn/aUS$6.97m
V9Z Aceragen
0.4xn/aUS$3.12m
PA8 Paion
0.2x30.2%US$2.78m
V9Z Aceragen
0.3x-161.8%US$2.18m
4TO 5.8xIndustry Avg. 7.9xNo. of Companies6PS0612182430+
6 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 4TO is good value based on its Price-To-Sales Ratio (5.8x) compared to the European Biotechs industry average (8x).

Price to Sales Ratio vs Fair Ratio

What is 4TO's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

4TO PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio5.8x
Fair PS Ratio21.2x

Price-To-Sales vs Fair Ratio: 4TO is good value based on its Price-To-Sales Ratio (5.8x) compared to the estimated Fair Price-To-Sales Ratio (21.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Amneal Pharmaceuticals

US$2.6b

Develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.

2DT

US$7.70

7D

-4.3%

1Y

91.5%

Teva Pharmaceutical Industries

US$19.4b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEV

US$16.25

7D

2.5%

1Y

89.8%

Merck

US$252.6b

Operates as a healthcare company worldwide.

6MK

US$97.10

7D

6.7%

1Y

3.9%